

Regimen Monograph

[Regimen Name](#) | [Drug Regimen](#) | [Cycle Frequency](#) | [Premedication and Supportive Measures](#) | [Dose Modifications](#) | [Adverse Effects](#) | [Interactions](#) | [Drug Administration and Special Precautions](#) | [Recommended Clinical Monitoring](#) | [Administrative Information](#) | [References](#) | [Other Notes](#) | [Disclaimer](#)

A - Regimen Name

ANAS Regimen

Anastrozole

Disease Site Breast
Gynecologic - Endometrial

Intent Palliative

Regimen Category **Evidence-Informed :**

Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.

Rationale and Uses

- For the hormonal treatment of advanced breast cancer in postmenopausal women
- For the treatment of advanced endometrial cancer

Supplementary Public Funding [anastrozole](#)
ODB - General Benefit (anastrozole) ([ODB Formulary](#))

[back to top](#)

B - Drug Regimen[anastrozole](#)

1 mg

PO

Daily

[back to top](#)**C - Cycle Frequency****CONTINUOUS TREATMENT**

Until disease progression or unacceptable toxicity

[back to top](#)**D - Premedication and Supportive Measures**

Antiemetic Regimen: Not applicable

Other Supportive Care:

- Assess patient's risk factors for osteoporosis and consider calcium and vitamin D supplements and bisphosphonates where appropriate. Refer patients to the [Bone Health During Cancer Treatment](#) pamphlet for more information.

[back to top](#)**E - Dose Modifications**

Doses should be modified according to the protocol by which the patient is being treated.

Dosage with toxicity

Toxicity	Action
Myelosuppression	No adjustment required.
Severe hypercalcemia	Hold; discontinue if recurs.

Hepatic Impairment

Clearance is reduced by 30% in patients with cirrhosis, but plasma levels are within normal range.

Hepatic Impairment	Anastrozole Dose
Mild to Moderate	No adjustment is required.
Severe	Not studied; consider potential risk/benefit.

Renal Impairment

Clearance is reduced by 50% in severe renal impairment. However, renal excretion is a minor route of excretion and no adjustment is required.

Creatinine Clearance (mL/min)	Anastrozole Dose
≥ 30	No adjustment is required.
< 30	No adjustment is required. Consider potential risk/benefit.

Dosage in the Elderly

No dosage adjustment required.

[back to top](#)

F - Adverse Effects

Refer to [anastrozole](#) drug monograph(s) for additional details of adverse effects.

Common (25-49%)	Less common (10-24%)	Uncommon (< 10%), but may be severe or life-threatening
<ul style="list-style-type: none"> • Estrogen deprivation symptoms • Musculoskeletal pain 	<ul style="list-style-type: none"> • Fatigue • Mood changes (including depression) • Hypertension • Nausea, vomiting 	<ul style="list-style-type: none"> • Arterial and venous thromboembolism • Ischemic cardiovascular events • Endometrial cancer

	<ul style="list-style-type: none"> • Osteoporosis, fracture • Rash • Headache • Insomnia 	<ul style="list-style-type: none"> • Hypercalcemia • Vasculitis • Hypersensitivity • Erythema multiforme • Stevens-Johnson syndrome • ↑ LFTs • Cataract
--	--	--

[back to top](#)

G - Interactions

Refer to [anastrozole](#) drug monograph(s) for additional details.

- Do not co-administer with tamoxifen due to ↓ anastrozole concentration and no efficacy or safety benefit.
- Avoid estrogen-containing or estrogenic agents due to ↓ estrogen suppression.

[back to top](#)

H - Drug Administration and Special Precautions

Refer to [anastrozole](#) drug monograph(s) for additional details.

Administration:

- Administer anastrozole with or without food.
- Tablets should be swallowed whole with a glass of water at the same time each day.
- Missed doses should be taken as soon as possible, but only if there are at least 12 hours before the next dose is due.
- Store at room temperature (15 to 30°C).

Contraindications:

- Patients with hypersensitivity to the drug or any of its components
- Pregnant or lactating women

Warnings/Precautions:

- Use is not recommended in premenopausal women*.
- Use with caution in patients with known osteoporosis or risk factors for osteoporosis, in patients with pre-existing cardiovascular disorders, severe liver or renal impairment.
- Anastrozole has not been studied in patients with brain, leptomeningeal or pulmonary lymphangitic disease.
- Use of formulations containing lactose should be carefully considered in patients with hereditary galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption.

**not receiving ovarian suppression*

Pregnancy/Lactation:

- Anastrozole is **contraindicated** in pregnancy. Adequate contraception must be used by both sexes during treatment, and for at least **6 months** (general recommendation) after the last dose.
- Breastfeeding: **Contraindicated**
- Fertility effects: Probable

[back to top](#)

I - Recommended Clinical Monitoring

Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.

Recommended Clinical Monitoring

- Bone mineral density for patients at risk; Baseline and as clinically indicated
- Clinical toxicity assessment for fatigue, musculoskeletal, estrogen deprivation symptoms, mood changes (including depression), rash, edema, thromboembolism, cardiovascular, GI and GU effects; At each visit
- Grade toxicity using the current [NCI-CTCAE \(Common Terminology Criteria for Adverse Events\) version](#)

Suggested Clinical Monitoring

- Liver function tests; Baseline and as clinically indicated

- Electrolytes, including calcium; Baseline and as clinically indicated
- Cholesterol and lipid evaluation; Baseline and as clinically indicated

[back to top](#)

J - Administrative Information

Outpatient prescription for home administration.

[back to top](#)

K - References

Anastazole drug monograph. Ontario Health (Cancer Care Ontario).

Breast:

Bonnerterre J, Buzdar A, Nabholz JM et al. Anastrozole is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma. *Cancer* 2001; 92(9):2247-58.

Bonnerterre J, Thürlimann BJK, Robertson JFR et al. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. *Journal of Clin Oncology* 2000; 18(22):3748-57.

Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. *J Clin Oncol*, 1996 July;14(7):2000-11.

Buzdar A, Jonat W, Howell A, Jones SE, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. *Cancer* 1998;83(8):1142-52.

Nabholz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to Tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. *J Clin Oncol*, 2000;18(22):3758-67.

Endometrial:

Ethier JL, Desautels DN, Amir E, MacKay H. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. *Gynecologic Oncology* 2017;147:158-166.

September 2021 Updated adverse effects and monitoring sections

[back to top](#)

M - Disclaimer

Regimen Abstracts

A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.

Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.

Regimen Monographs

Refer to the [New Drug Funding Program](#) or [Ontario Public Drug Programs](#) websites for the most up-to-date public funding information.

The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the “Formulary”) is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.

The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.

Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.

While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.

CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent,

special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the Formulary.

[back to top](#)